Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

Amid continued escalations in the Middle East conflict, the Indian government is considering a temporary price hike between 10 and 15 percent for essential medicines, according to a media report.

The surge in prices for select medicines could lead to higher drug prices but potentially benefit Indian pharmaceutical manufacturers facing the brunt of the Iran war.

“The immediate net consumer impact could be 3-5 percent higher prices, or roughly similar to what consumers paid before the late-September cuts in GST rates,” said the report by Economic Times, citing top industry executives aware of the government’s discussions.

The proposal was reportedly floated after several top drugmakers raised concerns about the sharp increase in prices of solvents and active pharmaceutical ingredients (APIs) due to global supply disruptions.

The price hike is expected to remain for up to four months and will be rolled back once the input cost stabilizes, the report said.

Further, it cited a senior government official saying that they have received the industry proposal for a price hike, but the decision to implement depends "on how long the geopolitical tension in West Asia lasts".

Increasing Raw Material Costs Drive Up Medical Device Prices

HealthandMe had earlier reported that the ongoing conflict has already spiked prices for medical devices—specifically plastics for syringes and catheters—due to the rising cost of raw materials. If disruptions persist, it can also warn of potential shortages.

“A shortage of liquid helium could impact the installation of new MRI scanners, each of which requires around 1,500 liters for the initial magnet fill. Supply disruptions linked to the war may delay new installations and push up costs, as helium prices are likely to rise amid tighter availability,” Dr. Harsh Mahajan, Mentor FICCI & Founder Mahajan Imaging & Labs, told HealthandMe.

The expert noted that there is no immediate concern for existing MRI machines. It is because most currently installed scanners use K4 technology with zero boil-off systems, allowing them to operate efficiently without frequent helium refills.

“Typically, a top-up is needed only once every three years, when the magnet’s cold head is replaced. As a result, the existing installed base is expected to continue functioning without disruption in the near term,” Dr. Mahajan said.

Also read: Report Claims Mojtaba Khamenei ‘Incapacitated’: What Does This Mean Medically

Long-term Hormuz Blockade Can Affect Critical Medical Supplies

However, the rapidly deteriorating situations and a longer blockade of Hormuz can lead to “substantial price increases, longer lead times, and highly elevated freight costs, which are pressuring cost structures and planning cycles”.

According to Rajiv Nath, AiMeD, the evolving global supply chain dynamics require close monitoring to prevent impacts on production timelines and industry stability.

The Medical Technology Association of India (MTaI) also warned that the ongoing US/Israel-Iran conflict and disruption in the Strait of Hormuz directly threaten India’s access to critical and life-saving medical technologies.

"Modern healthcare systems operate on just-in-time inventory models with minimal buffer stock. When large consignments - like those shipped by sea - are delayed or stranded, there is simply not enough inventory in the system to compensate, even through costlier alternatives like air freight," Pavan Choudary, Chairman, MTaI, told HealthandMe.

He also noted that shipment delays beyond March 31 can lead to "budget lapse, forcing a fresh approval cycle - thereby compounding delays that often stretch to months". It is because many public institutions in India front-load procurement toward the financial year-end.

Tech giant Amazon’s cloud unit has launched a new AI-powered application, Amazon Bio Discovery, that will help scientists design and test novel drugs more quickly, bringing new medical treatments to patients faster.

Developed by Amazon Web Services, the new agentic AI application—a smart assistant that automates complex tasks—helps scientists select the right models for their research goals, optimize the inputs, and evaluate candidates for experimentation.

"AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise," said Rajiv Chopra, vice president of AWS Healthcare AI and Life Sciences.

"These AI systems can help scientists design drug molecules, coordinate testing, learn from results, and get smarter with each experiment. This combination of cutting-edge AI and the robust, secure infrastructure AWS has built for regulated industries allows scientists to accelerate antibody discovery in ways that weren't possible before," Chopra added.

How Amazon Bio Discovery Will Help Boost Drug Discovery

With the help of Amazon Bio Discovery, scientists can run complex computational workflows ‌without writing code.

Notably, the platform also gives scientists direct access to a broad catalog of specialized AI models called biological foundation models (bioFMs) that are trained on vast biological datasets. These models generate and evaluate potential drug molecules, known as candidates, helping scientists accelerate antibody therapies during the early stages of drug discovery.

Also read: India Must Integrate Technology To Build Preventive, Holistic Healthcare: Experts

Amazon Bio Discovery also enables scientists to securely feed prior experimental data from their organization's lab results into the application. They can use their own lab data to train custom models with just a few clicks—no need to build complex training pipelines or write custom code.

Amazon Bio Discovery also provides three key capabilities:

• a benchmarked library of AI models and analysis packages,
• an AI agent that helps researchers design experiments,
• integrated lab partners that test the most promising antibody candidates and route results back to the scientists.

Amazon Bio Discovery: Early adopters

Amazon Bio Discovery provides complete data isolation and gives customers ownership over all their proprietary data and intellectual property.

According to AWS, Bayer, the Broad Institute, Fred Hutch Cancer Center, and Voyager Therapeutics are among early adopters, and 19 of the top 20 ‌global pharmaceutical ⁠companies already use its cloud services.

In a collaboration with Memorial Sloan Kettering Cancer Center, AWS said the platform used multiple models to generate nearly 300,000 novel antibody molecules and narrow them to 100,000 candidates for lab testing by partner Twist Bioscience, compressing work that can take months ⁠into weeks.

Surging AI Adoption in Drug Development

Drugmakers and technology companies have stepped up efforts to use AI to accelerate drug development.

Recently, Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced a "strategic partnership" with OpenAI to accelerate the development of new medications.

Read More: Telangana, Astrazeneca India To Launch AI-powered Lung Cancer Screening In Public Hospitals

Novo Nordisk is banking heavily on AI to test new treatments and vaccines and bring them to market faster for less money.

In 2024, Boston Consulting Group ⁠and Merck announced GenAI Collaboration with Merck. The collaboration will initially focus on disease networks and pathways for chronic and degenerative diseases.

Diabetes patients rely upon metformin for controlling their blood sugar and insulin levels. Now, a new study claims that this common diabetes drug has many other health benefits to offer, and these can mimic the benefits of 'intense workouts.' The diabetes drug metformin is used by millions around the world who are struggling with this lifestyle disorder—it releases weight-regulating compounds in the body, the same ones that are released during workouts in inactive people. American scientists found that the drug can have a positive impact on a sedentary lifestyle—find out how.

Also Read: The 'Cicada' COVID Variant: A New Name, A Familiar Landscape

What is metformin?

Are workouts necessary during cancer treatment?

How does metformin mimic the benefits of workouts?

Exercising benefits the body by releasing hormones such as oxytocin and dopamine. Researchers from the Sylvester Comprehensive Cancer Center explored whether these could be triggered without exercise and whether metformin could do that. They noted that while the drug cannot fully replace workouts as part of a healthy routine, there is a need to understand how a widely used drug can be beneficial for metabolic health during prostate cancer treatment.

N-lactoyl-phenylalanine, or Lac-Phe, is a molecule that spikes after an intense workout session, and it also regulates appetite and calorie burning. Scientists found that Lac-Phe levels were higher in metformin users even when they were not working out. The Sylvester team noted that prostate cancer patients often struggle with poor blood sugar control, heart disease risk, and weight gain due to hormone therapy. They then took blood samples from 29 people and found that the patients who took metformin had similar Lac-Phe levels to people who were engaged in strenuous workouts. This was noted even when the patients were not exercising. However, metformin did not have an impact on prostate tumours.

The study was published in the EMBO Molecular Medicine journal.